Nome |
# |
Peptide Receptor Radionuclide Therapy for Advanced Neuroendocrine Tumors, file e309ade1-8e2a-3969-e053-3a05fe0a2c94
|
360
|
68 Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients, file e309ade2-01e2-3969-e053-3a05fe0a2c94
|
277
|
Development of sentinel node localization and ROLL in breast cancer in Europe, file e309ade1-7592-3969-e053-3a05fe0a2c94
|
191
|
Improper use of "radioguided occult lesion localization" (ROLL) technique leads to misleading conclusions, file e309ade1-89a3-3969-e053-3a05fe0a2c94
|
189
|
Early use of abiraterone and radium-223 in metastatic prostate cancer, file e309ade2-3c33-3969-e053-3a05fe0a2c94
|
176
|
Dosimetry of 177Lu-PSMA-617 after mannitol infusion and glutamate tablet administration: Preliminary results of EUDRACT/RSO 2016-002732-32 IRST protocol, file e309ade2-1d64-3969-e053-3a05fe0a2c94
|
171
|
A new microdispersed albumin derivative potentially useful for radio-guided surgery of occult breast cancer lesions, file e309ade2-3b02-3969-e053-3a05fe0a2c94
|
138
|
Interim analysis of the REASSURE (Radium-223 alpha Emitter Agent in non-intervention Safety Study in mCRPC popUlation for long-teRm Evaluation) study: patient characteristics and safety according to prior use of chemotherapy in routine clinical practice, file e309ade2-3b85-3969-e053-3a05fe0a2c94
|
127
|
Eleven-year experience with the avidin-biotin pretargeting system in glioblastoma: Toxicity, efficacy and survival, file e309ade1-8546-3969-e053-3a05fe0a2c94
|
124
|
Positron emission tomography in the diagnostic work-up of screening-detected lung nodules, file e309ade1-82b8-3969-e053-3a05fe0a2c94
|
118
|
Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours, file e309ade1-8490-3969-e053-3a05fe0a2c94
|
101
|
PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis, file e309ade1-c505-3969-e053-3a05fe0a2c94
|
101
|
Erratum to: Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE, file e309ade1-7a71-3969-e053-3a05fe0a2c94
|
99
|
Evaluation of response to immunotherapy: new challenges and opportunities for PET imaging, file e309ade1-7c57-3969-e053-3a05fe0a2c94
|
89
|
Yttrium-labelled peptides for therapy of NET, file e309ade1-85e4-3969-e053-3a05fe0a2c94
|
86
|
Investigation of 90Y-avidin for prostate cancer brachytherapy: A dosimetric model for a phase I-II clinical study, file e309ade1-8d53-3969-e053-3a05fe0a2c94
|
65
|
A novel radioguided surgery technique exploiting β- decays, file e309ade1-8e28-3969-e053-3a05fe0a2c94
|
60
|
Texture analysis in 177Lu SPECT phantom images: Statistical assessment of uniformity requirements using texture features, file e309ade3-aff6-3969-e053-3a05fe0a2c94
|
60
|
Intramedullary spinal cord metastases from breast cancer: Detection with 18F-FDG PET/CT, file e309ade1-8a44-3969-e053-3a05fe0a2c94
|
58
|
Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: Efficacy profile, safety, and quality of life, file e309ade1-7803-3969-e053-3a05fe0a2c94
|
56
|
Use of the FLUKA Monte Carlo code for 3D patient-specific dosimetry on PET-CT and SPECT-CT images, file e309ade2-3151-3969-e053-3a05fe0a2c94
|
53
|
Atypical primary pulmonary meningioma: A report of a case suspected of being a lung metastasis, file e309ade1-7c59-3969-e053-3a05fe0a2c94
|
49
|
Secondary acute myeloid leukaemia after peptide receptor radionuclide therapy, file e309ade1-8d0a-3969-e053-3a05fe0a2c94
|
48
|
CAR-T cell therapy: A potential new strategy against prostate cancer, file e309ade2-e3be-3969-e053-3a05fe0a2c94
|
46
|
3D dosimetry in patients with early breast cancer undergoing Intraoperative Avidination for Radionuclide Therapy (IART®) combined with external beam radiation therapy, file e309ade1-83d7-3969-e053-3a05fe0a2c94
|
43
|
Quantitative accuracy of177Lu SPECT imaging for molecular radiotherapy, file e309ade1-ae1a-3969-e053-3a05fe0a2c94
|
41
|
Spotlight on PSMA as a new theranostic biomarker for bladder cancer, file e309ade4-e638-3969-e053-3a05fe0a2c94
|
40
|
PET/CT and breast cancer subtypes, file e309ade1-909f-3969-e053-3a05fe0a2c94
|
39
|
Dosimetric Approaches for Radioimmunotherapy of Non-Hodgkin Lymphoma in Myeloablative Setting, file e309ade5-42a1-3969-e053-3a05fe0a2c94
|
39
|
Preoperative PET/CT in earlystage breast cancer: Is the TNM classification enough?, file e309ade1-8a46-3969-e053-3a05fe0a2c94
|
37
|
Is [18F] fluorodeoxyglucose uptake by the primary tumor a prognostic factor in breast cancer?, file e309ade1-8cdf-3969-e053-3a05fe0a2c94
|
36
|
Prostate-specific membrane antigen and renal cell carcinoma: A new diagnostic and therapeutic target?, file e309ade2-b504-3969-e053-3a05fe0a2c94
|
36
|
Dosimetric issues associated with percutaneous ablation of small liver lesions with 90Y, file e309ade2-e564-3969-e053-3a05fe0a2c94
|
12
|
Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcome, file e309ade4-e416-3969-e053-3a05fe0a2c94
|
11
|
A metastatic tumor is no different to a viral pandemic: lessons learnt from COVID-19 may teach us to change the PRRT paradigm, file e309ade2-e5c6-3969-e053-3a05fe0a2c94
|
10
|
Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trials, file a75a43a0-f18f-4ec5-891b-97bf4a609a1c
|
9
|
177Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study, file e309ade2-e5cf-3969-e053-3a05fe0a2c94
|
9
|
68ga-psma-11 pet/ct-guided stereotactic body radiation therapy retreatment in prostate cancer patients with psa failure after salvage radiotherapy, file e309ade4-e04a-3969-e053-3a05fe0a2c94
|
9
|
[18 f]f-psma-1007 radiolabelling without an on-site cyclotron: A quality issue, file e309ade4-e5bc-3969-e053-3a05fe0a2c94
|
8
|
PET/CT in Multiple Myeloma: Beyond FDG, file e309ade4-f2d1-3969-e053-3a05fe0a2c94
|
8
|
Targeted Alpha Therapy in mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients: Predictive Dosimetry and Toxicity Modeling of 225Ac-PSMA (Prostate-Specific Membrane Antigen), file e309ade2-e562-3969-e053-3a05fe0a2c94
|
7
|
Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging, file e309ade4-e411-3969-e053-3a05fe0a2c94
|
7
|
177 lu-psma radioligand therapy is favorable as third-line treatment of patients with metastatic castration-resistant prostate cancer. A systematic review and network meta-analysis of randomized controlled trials, file e309ade4-e9fb-3969-e053-3a05fe0a2c94
|
7
|
Optimizing psma radioligand therapy for patients with metastatic castration-resistant prostate cancer. A systematic review and meta-analysis, file e309ade5-3bcd-3969-e053-3a05fe0a2c94
|
7
|
Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study, file e309ade2-e55a-3969-e053-3a05fe0a2c94
|
6
|
Exploratory Analysis of 18F-3’-deoxy-3’-fluorothymidine (18F-FLT) PET/CT-Based Radiomics for the Early Evaluation of Response to Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer, file e309ade4-e5ba-3969-e053-3a05fe0a2c94
|
6
|
Importance of pet with 68ga-labeled somatostatin analogs, file e309ade4-e04c-3969-e053-3a05fe0a2c94
|
5
|
Targeted radioactive therapy for prostate cancer, file e309ade4-e636-3969-e053-3a05fe0a2c94
|
5
|
Radiology imaging management in an Italian cancer center (IRST IRCCS) during the COVID-19 pandemic, file e309ade5-07ca-3969-e053-3a05fe0a2c94
|
5
|
Diagnostic and Prognostic Potential of 18F-FET PET in the Differential Diagnosis of Glioma Recurrence and Treatment-Induced Changes After Chemoradiation Therapy, file e309ade5-4096-3969-e053-3a05fe0a2c94
|
5
|
Peptide receptor radionuclide therapy with 177Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and 18F-FDG PET, file e309ade1-829f-3969-e053-3a05fe0a2c94
|
4
|
PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest, file 085b77f4-afb5-48e9-9395-4233c4e71420
|
3
|
Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors, file 35a623f5-dfcb-4716-8085-db13a7b9a994
|
3
|
Feasibility and utility of re-treatment with 177Lu-DOTATATE in GEP-NENs relapsed after treatment with 90Y-DOTATOC, file e309ade1-7612-3969-e053-3a05fe0a2c94
|
3
|
Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE, file e309ade1-78e1-3969-e053-3a05fe0a2c94
|
3
|
Yttrium-based therapy for neuroendocrine tumors, file e309ade1-79a7-3969-e053-3a05fe0a2c94
|
3
|
18F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide, file e309ade1-826a-3969-e053-3a05fe0a2c94
|
3
|
68 Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients, file e309ade3-58c5-3969-e053-3a05fe0a2c94
|
3
|
Are we ready for an early evaluation of the response of axillary lymph node metastases to neoadjuvant therapy?, file e309ade1-88cb-3969-e053-3a05fe0a2c94
|
2
|
OXavidin for tissue targeting biotinylated therapeutics, file e309ade1-8b32-3969-e053-3a05fe0a2c94
|
2
|
A parathyroid carcinoma within a cold thyroid nodule, file e309ade1-8b35-3969-e053-3a05fe0a2c94
|
2
|
Kidney dosimetry in 177Lu and 90Y peptide receptor radionuclide therapy: Influence of image timing, time-activity integration method, and risk factors, file e309ade1-8b4d-3969-e053-3a05fe0a2c94
|
2
|
Muscle metastases from gallbladder cancer, file e309ade1-8d12-3969-e053-3a05fe0a2c94
|
2
|
Detection of a cardiac mass by [18F]FDG-PET/CT: A rare case, file e309ade1-a5bc-3969-e053-3a05fe0a2c94
|
2
|
Development of sentinel node biopsy, ROLL and IART in early breast cancer at the European Institute of Oncology, Milan (IEO), file e309ade1-b694-3969-e053-3a05fe0a2c94
|
2
|
Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer, file e309ade1-b8ee-3969-e053-3a05fe0a2c94
|
2
|
Reduction of68Ga-PSMA renal uptake with mannitol infusion: preliminary results, file e309ade1-c4f7-3969-e053-3a05fe0a2c94
|
2
|
68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors, file e309ade2-bead-3969-e053-3a05fe0a2c94
|
2
|
SUV95th as a Reliable Alternative to SUVmax for Determining Renal Uptake in [68Ga] PSMA PET/CT, file e309ade2-e5c5-3969-e053-3a05fe0a2c94
|
2
|
Dosimetric Approaches for Radioimmunotherapy of Non-Hodgkin Lymphoma in Myeloablative Setting, file e309ade4-f56d-3969-e053-3a05fe0a2c94
|
2
|
Adoptive immunotherapy by avidin-driven cytotoxic T lymphocyte-tumor bridging, file 1614eb81-00b8-4483-8af0-6a275e7358f1
|
1
|
Gene transcript analysis blood values correlate with 68Ga-DOTA-somatostatin analog (SSA) PET/CT imaging in neuroendocrine tumors and can define disease status, file e309ade1-7958-3969-e053-3a05fe0a2c94
|
1
|
Peptide Receptor Radionuclide Therapy (PRRT): clinical Application, file e309ade1-795b-3969-e053-3a05fe0a2c94
|
1
|
Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors, file e309ade1-7972-3969-e053-3a05fe0a2c94
|
1
|
Design and solid phase synthesis of new DOTA conjugated (+)-biotin dimers planned to develop molecular weight-tuned avidin oligomers, file e309ade1-7b86-3969-e053-3a05fe0a2c94
|
1
|
Ipilimumab-induced immunomediated adverse events: possible pitfalls in (18)F-FDG PET/CT interpretation, file e309ade1-7c2e-3969-e053-3a05fe0a2c94
|
1
|
Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors, file e309ade1-82a4-3969-e053-3a05fe0a2c94
|
1
|
Erratum to: 18F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide [Eur J Nucl Med Mol Imaging, DOI 10.1007/s00259-015-3042-5], file e309ade1-82dc-3969-e053-3a05fe0a2c94
|
1
|
Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies, file e309ade1-85e7-3969-e053-3a05fe0a2c94
|
1
|
Intraoperative beta- detecting probe for radio-guided surgery of brain tumors, file e309ade1-878e-3969-e053-3a05fe0a2c94
|
1
|
Treatment with the radiolabelled somatostatin analog Lu-DOTATATE for advanced pancreatic neuroendocrine tumors, file e309ade1-88b7-3969-e053-3a05fe0a2c94
|
1
|
Use of the FLUKA Monte Carlo code for 3D patient-specific dosimetry on PET-CT and SPECT-CT images, file e309ade1-8a48-3969-e053-3a05fe0a2c94
|
1
|
Axillary metastases in breast cancer patients with negative sentinel nodes: A follow-up of 3548 cases, file e309ade1-8a7b-3969-e053-3a05fe0a2c94
|
1
|
Hibernoma mimicking metastasis on positron emission tomography-computed tomography imaging: A misleading finding in oncologic patient follow-up, file e309ade1-8aab-3969-e053-3a05fe0a2c94
|
1
|
Roles of computed tomography and [ 18F]fluorodeoxyglucose- positron emission tomography/computed tomography in the characterization of multiple solitary solid lung nodules, file e309ade1-8d0d-3969-e053-3a05fe0a2c94
|
1
|
PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest, file e309ade2-e3b7-3969-e053-3a05fe0a2c94
|
1
|
Re: Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, et al. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol. 2020;77: 508–47 https://doi.org/10.1016/j.eururo.2020.01.012, file e309ade2-e3b9-3969-e053-3a05fe0a2c94
|
1
|
Clinical value of negative 68Ga-PSMA PET/CT in the management of biochemical recurrent prostate cancer patients, file e309ade2-e3bb-3969-e053-3a05fe0a2c94
|
1
|
Dosimetry and safety of 177Lu PSMA-617 along with polyglutamate parotid gland protector: preliminary results in metastatic castration-resistant prostate cancer patients, file e309ade2-e55c-3969-e053-3a05fe0a2c94
|
1
|
Combination radium-223 therapies in patients with bone metastases from castration-resistant prostate cancer: A review, file e309ade2-e5cd-3969-e053-3a05fe0a2c94
|
1
|
Investigation of receptor radionuclide therapy with 177Lu-DOTATATE in patients with GEP-NEN and a high Ki-67 proliferation index, file e309ade3-50a7-3969-e053-3a05fe0a2c94
|
1
|
Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors, file e309ade4-cfbb-3969-e053-3a05fe0a2c94
|
1
|
Totale |
3.360 |